Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 1672 · Maintaining Investments in New Innovation Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+3 −1Shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in paragraph (1)(A)(ii), by inserting (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years) after 7 years; and

  2. Carried out:

    by adding at the end the following new paragraph:(4) Advanced drug product defined.— For purposes of paragraph (1)(A)(ii), the term “advanced drug product” means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result …

§ 1320f–1(e)(1)In general(A)–(B)

Start of § 1320f–1 to (e)(1)(A) unchanged ·

(i) that is approved under section 355(c) of title 21 and is marketed pursuant to such approval;

(ii) for which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years [inserted: (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years) ]will have elapsed since the date of such approval; and

(iii) that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title.

(B) Biological products A biological product—

§ 1320f–1(e)–(f)

(e)(1)(B)(i)–(3)(B)(ii) unchanged ·

(iii) with respect to a subsequent initial price applicability year, is less than, during the most recent 12-month period applicable under subparagraphs (A) and (B) of subsection (d)(1) for such year, the dollar amount specified in this subparagraph for the previous initial price applicability year increased by the annual percentage increase in such consumer price index for the 12-month period ending on September 30 of the year prior to the year of the selected drug publication date with respect to such subsequent initial price applicability year.

(C) Plasma-derived products A biological product that is derived from human whole blood or plasma.

(4) [inserted: Advanced drug product defined.—] [inserted: For purposes of paragraph (1)(A)(ii), the term “advanced drug product” means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product.]

(f) Special rule to delay selection and negotiation of biologics for biosimilar market entry

(1) Application

(A) In general Subject to subparagraph (B), in the case of a biological product that would (but for this subsection) be an extended-monopoly drug (as defined in section 1320f–3(c)(4) of this title) included as a selected drug on the list published under subsection (a) with respect to an initial price applicability year, the rules described in paragraph (2) shall apply if the Secretary determines that there is a high likelihood (as described in paragraph (3)) that a biosimilar biological product (for which such biological product will be the reference product) will be licensed and marketed under section 262(k) of this title before the date that is 2 years after the selected drug publication date with respect to such initial price applicability year.

Rest of § 1320f–1 unchanged ·

Step through the changes